
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI Inc demonstrates a positive outlook based on its notable revenue growth and strong market positioning within the healthcare technology sector. The company reported total revenue growth of 84.7% year-over-year, driven primarily by a remarkable 117.2% increase in Genomics revenue to $252.9 million, alongside a 26.1% rise in Data & Other revenue. Furthermore, expectations for higher average selling prices (ASPs) from its xF liquid biopsy assay and a shift to its xT CDx test indicate a promising trajectory for continued expansion and profitability in the coming quarters.
Bears say
Tempus AI Inc has seen a notable decline in gross margins within its Data & Other segment, falling from 76.8% in Q3 of the previous year to 69.7% in the most recent quarter, indicating potential challenges in maintaining profitability. The company continues to incur significant losses and has a sizable debt load of $518.8 million against cash reserves of $764.3 million, raising concerns about its financial sustainability and ability to achieve positive operating cash flow, which decreased by $168.5 million year-over-year. Additionally, there are substantial risks related to slower-than-expected sales growth, regulatory hurdles, and customer retention, all contributing to an overall negative outlook for Tempus AI's future performance.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares